Targeting Bladder Tumor Cells<i>In vivo</i>and in the Urine with a Peptide Identified by Phage Display

Lee, Seung Min; Lee, Eun Ju; Hong, Hai Yan; Kwon, Minji; Kwon, Tae Hwan; Choi, Je Yong; Park, Rang Woon; Kwon, Tae Gyun; Yoo, Eun Sang; Yoon, Gil Suk; Kim, In San; Ruoslahti, Erkki; Lee, Byung Heon

doi:10.1158/1541-7786.mcr-06-0069

Cited by 92 publications

(87 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result was demonstrated in previous free peptide studies, showing that CSNRDARRC has high affinity for human bladder tumors. 30,35 We previously reported the high affinity of this peptide to various bladder cancer cells, including human, murine, and canine cells 36 ( Figure 8A and B). Here, we incubated the pMCNPs with canine bladder cancer cells (K9TCC).…”

Section: Intracellular Uptake Of Pmcnps By K9tcc Bladder Cancer Cellsmentioning

confidence: 81%

See 1 more Smart Citation

Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging

Key¹,

Dhawan²,

Cooper³

et al. 2016

IJN

View full text Add to dashboard Cite

While current imaging modalities, such as magnetic resonance imaging (MRI), computed tomography, and positron emission tomography, play an important role in detecting tumors in the body, no single-modality imaging possesses all the functions needed for a complete diagnostic imaging, such as spatial resolution, signal sensitivity, and tissue penetration depth. For this reason, multimodal imaging strategies have become promising tools for advanced biomedical research and cancer diagnostics and therapeutics. In designing multimodal nanoparticles, the physicochemical properties of the nanoparticles should be engineered so that they successfully accumulate at the tumor site and minimize nonspecific uptake by other organs. Finely altering the nano-scale properties can dramatically change the biodistribution and tumor accumulation of nanoparticles in the body. In this study, we engineered multimodal nanoparticles for both MRI, by using ferrimagnetic nanocubes (NCs), and near infrared fluorescence imaging, by using cyanine 5.5 fluorescence molecules. We changed the physicochemical properties of glycol chitosan nanoparticles by conjugating bladder cancer-targeting peptides and loading many ferrimagnetic iron oxide NCs per glycol chitosan nanoparticle to improve MRI contrast. The 22 nm ferrimagnetic NCs were stabilized in physiological conditions by encapsulating them within modified chitosan nanoparticles. The multimodal nanoparticles were compared with in vivo MRI and near infrared fluorescent systems. We demonstrated significant and important changes in the biodistribution and tumor accumulation of nanoparticles with different physicochemical properties. Finally, we demonstrated that multimodal nanoparticles specifically visualize small tumors and show minimal accumulation in other organs. This work reveals the importance of finely modulating physicochemical properties in designing multimodal nanoparticles for bladder cancer imaging.

show abstract

Section: Intracellular Uptake Of Pmcnps By K9tcc Bladder Cancer Cellsmentioning

confidence: 81%

“…11,30 The biodistribution and tumor accumulation of the modified nanoparticles in each step were compared in parallel through in vivo systems. We demonstrated that adding new components, such as new MR contrast agents or targeting ligands, clearly changed its in vivo biodistribution by altering their physicochemical properties of the particles.…”

mentioning

confidence: 99%

Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging

Key¹,

Dhawan²,

Cooper³

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…There are many advantages to the use of small peptides including low cost, absence of significant immunogenicity, and ease of coupling to cytotoxic agents. The most important advantage of peptides is their versatility (Aggarwal et al, 2006;Jäger et al, 2007;Lee et al, 2007;Rasmussen et al, 2002). For example, tumor binding peptide sequences can be incorporated into the coat proteins of viruses (Grifman et al, 2001;White et al, 2004), and novel targeting tools, such as liposomes and nanoparticles, can be used together with the peptides (Hajitou et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, RNA aptamers have been developed for use as targeting and imaging tools (Hicke et al, 2001;. However, to expand the potential utility of TNC as a tumor microenvironment target, a versatile alternative molecule such as a small peptide should also be developed (Aggarwal et al, 2006;Jäger et al, 2007;Lee et al, 2007;Rasmussen et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Selection and Characterization of Tenascin C Targeting Peptide

Kim

Choi

et al. 2012

Molecules and Cells

View full text Add to dashboard Cite

Since tenascin C is a factor expressed highly in the tumorassociated matrix, it would be a desirable first step for targeting the tumor-specific microenvironment. In fact, a high level of tenascin C expression has been reported in most solid tumors, including lung cancer, colon cancer and glioblastoma. Therefore, the targeted binding of tenascin C in tumor stroma would inhibit tumor metastasis by modulating cancer cell growth and migration. We isolated a peptide that bound to tenascin C by phage display peptide library selection, and the selected peptide specifically recognized tenascin C protein in xenograft mouse tissue. We also observed exclusive staining of tenascin C by the selected peptide in tumor patient tissues. Moreover, the peptide reduced tenascin C-induced cell rounding and migration. We propose that the tenascin C targeting peptide may be useful as a specific anti-cancer diagnostic and therapeutic tool for most human solid tumors.

show abstract

“…A Bld-1 peptide of CSNRDARRC, which binds to bladder tumor cell, has been identified by phage display [102]. Jung et al combined the tumor targeting peptide Bld-1 with a pro-apoptosis D (KLA) 2 and formed a hybrid peptide of Bld-1-kla.…”

Section: Bld-1mentioning

confidence: 99%

Design and Modification of Anticancer Peptides

Hu¹,

Chen²,

Zhao³

et al. 2016

Drug Des

View full text Add to dashboard Cite

Cancer is a great concern in the public health and development of novel therapeutic agent or strategy become urgently. Anticancer peptides (ACPs) have become promising anticancer drug candidate molecules due to their several extraordinary properties, such as small size, high activity, low immunogenicity, good biocompatibility, diversity of sequence and more modification sites for the functional molecules. However, the low stability and short half-life of peptides are the major barriers for the application. In this review, we focus on the methods of peptide design and modification to improve the stability, half-life time and specificity of ACPs, which including amino acid substitution, cyclization, hybridization, fragmentization, modification of C-and N-terminal of peptide by polymer or targeting molecules, etc.modification of C-and N-terminal of peptide by polymer or targeting molecules, etc. The schematic diagram of major design and modification strategies of ACPs are shown in Figure 1.

show abstract

Targeting Bladder Tumor CellsIn vivoand in the Urine with a Peptide Identified by Phage Display

Cited by 92 publications

References 29 publications

Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging

Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging

Selection and Characterization of Tenascin C Targeting Peptide

Design and Modification of Anticancer Peptides

Contact Info

Product

Resources

About